Request Demo
Last update 08 May 2025
Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
Last update 08 May 2025
Overview
Basic Info
Drug Type Recombinant protein, Prophylactic vaccine |
Synonyms 重组新冠病毒Beta/Omicron(BA.1/BQ.1.1/XBB.1)变异株S三聚体蛋白疫苗(神州细胞), 重组新冠病毒Beta/Omicron变异株S三聚体蛋白疫苗 (神州细胞) + [1] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Dec 2023), |
RegulationEmergency Use Authorization (China) |
Login to view timeline
Related
1
Clinical Trials associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)NCT05933512
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E-2 (COVID-19 Beta/Omicron (BA.1/BQ.1.1/XBB.1) Variants S-Trimer Vaccine) in Population Previously Vaccinated With mRNA COVID-19 Vaccine
100 Clinical Results associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
Login to view more data
100 Translational Medicine associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
Login to view more data
100 Patents (Medical) associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
Login to view more data
1
Literatures (Medical) associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)Vaccines
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
Article
Author: Qian, Gui ; Li, Tao ; Gao, Cuige ; Qiao, Liyang ; Xu, Haiyang ; Xu, Qinghua ; Tang, Jihai ; Tian, Yan ; Pang, Xingya ; Wu, Gang ; Han, Jun ; Xuan, Kun ; Zhu, Chaoyin ; Xie, Liangzhi ; Tian, Xuxin ; Yi, Jiang ; Li, Jinwei ; Li, Qingru ; Zha, Zhenqiu
100 Deals associated with Recombinant novel coronavirus Beta/Omicron (BA.1/BQ.1.1/XBB.1) S trimeric protein vaccine (Sinocelltech)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| COVID-19 | China | 01 Dec 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 2 | - | 10 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free